Table 1.
HLA frequencies in 80 patients with COVID‐19 previously HLA typed to support transplantation
|
HLA Allele Group |
COVID‐19 population Allele group carriage frequency (%; n = 80) |
Control Group A Allele group carriage frequency (%; n = 10,000) |
Control Group A p |
Control Group A p c |
Control Group B Allele group carriage frequency (%) (n = 308) |
Control Group B p |
Control Group B p c |
|---|---|---|---|---|---|---|---|
| HLA‐A*02 | 36.3 | 50.0 | .0179 | .0536 | 46.4 | — | — |
| HLA‐A*26 | 11.3 | 4.0 | .0049 | .0198 | 7.5 | — | — |
| HLA‐B*44 | 17.5 | 32.0 | .0052 | .0105 | 19.8 | — | — |
| HLA‐C*05 | 8.8 | 21.0 | .0054 | .0215 | 15.9 | — | — |
| HLA‐C*12 | 12.5 | 6.0 | .0286 | — | 11.7 | — | — |
| DRB1*15 | 40.0 | 28.0 | .0238 | — | 25.3 | .0121 | — |
| DRB1*04 | 22.5 | 35.0 | .0185 | — | 33.4 | — | — |
| DRB1*11 | 22.5 | 13.0 | .0185 | — | 18.8 | — | — |
| DRB1*07 | 16.3 | 26.0 | .0539 | — | 20.8 | — | — |
| DRB1*10 | 6.3 | 1.0 | .0014 | .0144 | 4.5 | — | — |
| DQB1*05 | 35.0 | 27.0 | — | — | 30.5 | — | — |
| DQB1*06 | 52.5 | 41.0 | .0402 | — | 36.0 | .0010 | .0523 |
The control frequencies are derived from Group A: (n = 10,000) deceased solid organ donors between November 1994 and December 2009 (https://nhsbtdbe.blob.core.windows.net/umbraco‐assets‐corp/2925/antigen.pdf) and Group B: a local (n = 308) wait‐listed renal patient cohort comprising the active wait list from Leeds (n = 150) and a randomly selected cohort (n = 158) from the Manchester centre. Only associations which demonstrated significance, or approached significance when compared with either control population are listed. Significance (Fisher's exact) is shown before (p) and after (p c) Bonferroni correction. Results which are not significant are represented by (−) in the table.